CellaVision AB presents the third quarter 2017 on October 25 at 11:00 CET
The information was submitted to the public on October 11, 2017 at 8:20 CET
CellaVision will publish the interim report for the third quarter on October 25, 2017 at 08:20 CET. The report will be available at www.cellavision.com
In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, CEO, will present and comment the report.
The presentation will be in English via a conference call or audio webcast:
http://www.financialhearings.com/event/10275
Phone number for the conference:
SE: +46856642696
UK: +442030089806
US: 18558315948
No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time in order to facilitate a timely start.
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replaces manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the market support organizations in the US, Canada, China, Sweden, Japan, UAE, Korea, Australia, France, Germany, Brazil and Great Britain. In 2016 sales were SEK 265 million and the company`s growth target is 15 % per year over an economic cycle. CellaVision`s registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Small Cap list. Read more at www.cellavision.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via GlobeNewswire
HUG#2141039
